Dr. Betty Pace, Augusta University, United States
Dr. Betty Sue Pace, MD, is a Professor with tenure at Augusta University, serving in the Departments of Pediatrics and Biochemistry & Molecular Biology. 🧬 She holds the prestigious Francis J. Tedesco Distinguished Chair in Pediatric Hematology/Oncology and is a member of the Georgia Cancer Center. 🌟 With a medical degree from the Medical College of Wisconsin and postdoctoral training at the University of Washington, Dr. Pace is a leader in sickle cell disease research. ❤️ She has directed major research centers and served on national committees, including NIH and ASH. 📚 Her work promotes diversity, inclusion, and scientific advancement.
Publication Profile
Scopus
🎓 Education & Training
Dr. Betty Sue Pace began her academic journey at Lake Forest College in 1973, later earning her B.S. in Mathematics from Marquette University in 1976. ➗ She pursued her M.D. in Medicine at the Medical College of Wisconsin, graduating in 1981. 🩺 Dr. Pace completed her Pediatric Internship and Residency (1981–1984) at the same institution’s Children’s Hospital. 👶 She further specialized through a Pediatric Hematology/Oncology Fellowship at the University of Colorado Health Sciences Center (1987–1990). 🧬 In 1990, she briefly served as a Locum Tenens Pediatrician before undertaking a Postdoctoral Research Fellowship at the University of Washington (1990–1994).
🏅 Awards & Honors
Dr. Betty Sue Pace has received numerous prestigious accolades throughout her career. 🌟 In 1981, she was honored with the Kaiser Foundation Merit Award, Mosby Mirror Award, and Alpha Omega Alpha induction. 🏆 A Harold Amos Scholar in 1990, she was later named among Popular Science’s “Brilliant 10” in 2003. 🧪 Her work earned her Lifetime Achievement (2007), Diversity Champion (2010), and Distinguished Researcher (2022) awards. 💼 She also established endowed scholarships in her name and currently serves as Editor-in-Chief of the Journal of Sickle Cell Disease (2025). 📰 Her honors reflect a legacy of excellence in science, service, and inclusion.
Research Focus
Dr. Betty S. Pace’s research is primarily centered on sickle cell disease (SCD), with a strong focus on oxidative stress, fetal hemoglobin induction, and gene regulation. 🧬 Her work explores epigenetic therapies, histone deacetylase inhibitors, and NRF2 activation to mitigate disease symptoms. 🧫 She utilizes transgenic models, CRISPR techniques, and microRNA therapies to induce fetal hemoglobin expression and reduce ferroptosis. 💉 Her interdisciplinary research bridges molecular biology, hematology, and genomic innovation, aiming to develop novel therapeutic strategies for SCD. 🧠 Through collaborative studies and translational science, she is advancing curative solutions and improving patient outcomes worldwide.
Publication Top Notes
📄 “Transsulfuration pathway activation attenuates oxidative stress and ferroptosis…” – Communications Biology, 2025 | Cited by: 1 📚🧬
📄 “CT-101 flips the switch to fetal hemoglobin expression…” – PLOS One, 2025 🧪🧬
📄 “Innovations in Drug Discovery for SCD Targeting Oxidative Stress and NRF2…” – Review, 2025 💊🧠
📄 “Endothelial ENaC-a Restrains Oxidative Stress in Lung Capillaries…” – Am J Respir Cell Mol Biol, 2025 | Cited by: 2 🫁🔬
📄 “Hematopoietic cell transplant vs standard care in adolescents…” – Blood Advances, 2025 🧫🧒
📄 “miR-29b induces fetal haemoglobin via promoter demethylation…” – Br J Haematol, 2025 🧬🧠
📄 “Correction to: CRISPR-mediated fetal chromatin domain ablations” – Scientific Reports, 2022 🧪📘
📄 “Telehealth Use Among People with SCD During COVID-19…” – Telemedicine & e-Health, 2024 | Cited by: 1 💻📞
📄 “Simvastatin-Mediated Nrf2 Activation in SCD Mice…” – Antioxidants, 2024 | Cited by: 2 🧬🛡️
📄 “Emergency Department Visits by Individuals With SCD (1999–2020)…” – Ajpm Focus, 2024 | Cited by: 6 🏥📈